Adaptive Biotechnologies (NASDAQ:ADPT – Get Rating) released its earnings results on Wednesday. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.06), Briefing.com reports. The firm had revenue of $37.65 million during the quarter, compared to analyst estimates of $36.81 million. Adaptive Biotechnologies had a negative return […]
Adaptive Biotechnologies Co. (NASDAQ:ADPT – Get Rating) was the target of a large increase in short interest in March. As of March 31st, there was short interest totalling 6,120,000 shares, an increase of 14.8% from the March 15th total of 5,330,000 shares. Based on an average daily volume of 952,800 shares, the days-to-cover ratio is […]
Adaptive Biotechnologies (NASDAQ:ADPT – Get Rating) and Acorda Therapeutics (NASDAQ:ACOR – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability. Analyst Ratings This is a breakdown of recent ratings […]
Adaptive Biotechnologies Co. (NASDAQ:ADPT – Get Rating) Director Michelle Renee Griffin sold 2,341 shares of the stock in a transaction on Monday, March 27th. The shares were sold at an average price of $8.49, for a total value of $19,875.09. Following the sale, the director now owns 20,627 shares in the company, valued at approximately […]
Adaptive Biotechnologies Co. (NASDAQ:ADPT – Get Rating) traded down 3.8% on Tuesday . The company traded as low as $8.34 and last traded at $8.39. 161,632 shares traded hands during trading, a decline of 83% from the average session volume of 959,535 shares. The stock had previously closed at $8.72. Analyst Upgrades and Downgrades Several […]